Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | OGFRL1 | Q5TC84 | 15/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928960 | 1.00 | HDAC1 (0.48) | HDAC1HDAC6HDAC3HDAC10OGFRL1 | |
| SCHEMBL4934143 | 0.90 | PDE10A (0.39) | HDAC1HDAC6HDAC3HDAC10OGFRL1 | |
| SCHEMBL4935846 | 0.90 | PDE10A (0.39) | HDAC1HDAC6HDAC3HDAC10OGFRL1 | |
| SCHEMBL4931965 | 0.89 | HDAC1 (0.45) | HDAC1OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4931988 | 0.89 | HDAC1 (0.45) | HDAC1OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4930759 | 0.84 | HDAC1 (0.40) | HDAC1HDAC6HDAC8 | |
| SCHEMBL4930747 | 0.84 | HDAC1 (0.40) | HDAC1HDAC6HDAC8 | |
| SCHEMBL4926676 | 0.83 | HDAC3 (0.52) | HDAC1HDAC6HDAC3HDAC10TP53 | |
| SCHEMBL4937187 | 0.83 | HDAC3 (0.52) | HDAC1HDAC6HDAC3HDAC10TP53 | |
| SCHEMBL4926659 | 0.83 | HDAC3 (0.52) | HDAC1HDAC6HDAC3HDAC10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | HDAC1 2/4885HDAC6 10/4885HDAC3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.